CA2586486A1 - Proteines contenant des motifs repetes riches en leucine (lrr) - Google Patents

Proteines contenant des motifs repetes riches en leucine (lrr) Download PDF

Info

Publication number
CA2586486A1
CA2586486A1 CA002586486A CA2586486A CA2586486A1 CA 2586486 A1 CA2586486 A1 CA 2586486A1 CA 002586486 A CA002586486 A CA 002586486A CA 2586486 A CA2586486 A CA 2586486A CA 2586486 A1 CA2586486 A1 CA 2586486A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
nucleic acid
disease
insp168
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002586486A
Other languages
English (en)
Inventor
David Michalovich
Simon John White
Melanie Yorke
Kinsey Maundrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ares Trading SA
Original Assignee
Ares Trading SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading SA filed Critical Ares Trading SA
Publication of CA2586486A1 publication Critical patent/CA2586486A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002586486A 2004-11-15 2005-11-15 Proteines contenant des motifs repetes riches en leucine (lrr) Abandoned CA2586486A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0425197.1 2004-11-15
GB0425197A GB0425197D0 (en) 2004-11-15 2004-11-15 Leucine-rich repeat (LRR) motif containing proteins
PCT/GB2005/004390 WO2006051333A2 (fr) 2004-11-15 2005-11-15 Proteines contenant des motifs repetes riches en leucine (lrr)

Publications (1)

Publication Number Publication Date
CA2586486A1 true CA2586486A1 (fr) 2006-05-18

Family

ID=33523767

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002586486A Abandoned CA2586486A1 (fr) 2004-11-15 2005-11-15 Proteines contenant des motifs repetes riches en leucine (lrr)

Country Status (7)

Country Link
EP (1) EP1814903A2 (fr)
JP (1) JP2008519593A (fr)
AU (1) AU2005303536A1 (fr)
CA (1) CA2586486A1 (fr)
GB (1) GB0425197D0 (fr)
IL (1) IL182960A0 (fr)
WO (1) WO2006051333A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116036239B (zh) * 2023-03-28 2023-06-23 中国人民解放军军事科学院军事医学研究院 Nep1-40在制备特异性抑制幻觉作用的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001128686A (ja) * 1999-11-09 2001-05-15 Tanabe Seiyaku Co Ltd 新規な蛋白質及びその遺伝子
AU2002366713A1 (en) * 2001-12-20 2003-07-09 Incyte Genomics, Inc. Nucleotide polymorphisms associated with osteoarthritis
EP1447413A3 (fr) * 2003-02-14 2006-01-04 Research Association for Biotechnology ADN complementaire humaine de pleine longueur

Also Published As

Publication number Publication date
AU2005303536A1 (en) 2006-05-18
JP2008519593A (ja) 2008-06-12
WO2006051333A3 (fr) 2006-07-20
IL182960A0 (en) 2007-08-19
GB0425197D0 (en) 2004-12-15
EP1814903A2 (fr) 2007-08-08
WO2006051333A2 (fr) 2006-05-18

Similar Documents

Publication Publication Date Title
US7622555B2 (en) Cytokine antagonist molecules
US8222371B2 (en) vWFA and/or ANT—IG domain containing proteins
US20080226640A1 (en) C1q Related Protein
US20080213286A1 (en) Mam Domain Containing Protein
WO2008015380A2 (fr) Protéine membranaire intégrale
AU2004203966A1 (en) Defensin proteins
US20100196349A1 (en) Reeler domain containing protein
EP1824881B1 (fr) Recepteur de proteines de type tgr3
US20100048467A1 (en) Cystine-Knot Fold Cytokine
US20090215672A1 (en) Cys-Rich, Cell Surface Glycoproteins
CA2586486A1 (fr) Proteines contenant des motifs repetes riches en leucine (lrr)
WO2007049065A2 (fr) Proteine contenant des domaines vwfa, collagene et kunitz
WO2008012505A2 (fr) Glycoprotéine membranaire ancrée par gpi
WO2007049062A2 (fr) Protéines contenant des domaines vwfa
US7514533B2 (en) TNF-like secreted protein
US20060216709A1 (en) Midkine-like protein
US20070264251A1 (en) C1q Related Protein
AU2003295100A1 (en) Midkine-like protein
WO2004007552A1 (fr) Recepteur de cytokine
WO2008012503A1 (fr) Homologue de pro4426
WO2007060431A1 (fr) Proteine a domaine(s) ntr de type netrine
WO2008032053A1 (fr) Variantes d'épissure fhr-4a
WO2007045911A1 (fr) Proteine membranaire integrale
WO2003104278A1 (fr) Proteine de type tnf
WO2007072011A1 (fr) Proteine de type recepteur de l'interleukine-9

Legal Events

Date Code Title Description
FZDE Discontinued